HCM ▲ +0.6% - HUTCHMED (China) Limited
$HCM - HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026
26-OCT-2026 04:30 AM ET
Share this post
More filings for $HCM
HCM ▲ +0.6% - HUTCHMED (China) LimitedOct 26, 2026HCM ▲ +3.9% - HUTCHMED (China) LimitedOct 21, 2026HCM ▲ +0.9% - HUTCHMED (China) LimitedSep 29, 2026HCM ▲ +2.1% - HUTCHMED (China) LimitedSep 24, 2026HCM ▲ +1.1% - HUTCHMED (China) LimitedSep 3, 2026
View full $HCM filing history →💬 Comments
Loading comments…
Leave a comment